Spiral Genetics, Microsoft to Bring Bioinformatics to Azure

Spiral Genetics, Inc. has delivered the BioGraph Suite, a powerful set of tools for the management and analysis of Next Generation Sequencing (NGS) genetic data, on Microsoft Azure.

“Microsoft Azure has allowed us to quickly deploy and deliver a scalable solution to our customers who need an enterprise-class bioinformatics solution,” said Adina Mangubat, CEO and Founder of Spiral Genetics, Inc.

To learn about the features of BioGraph Suite, and how it benefits from using Azure, download the datasheet and mini-case study.

David Heckerman, Distinguished Scientist of Microsoft, said, "The Azure cloud is the ideal platform for genomic analysis because it provides reliable and scalable compute resources with a selection of machine configurations that can be accessed from anywhere in the world, while offering enterprise-grade data security. And, with partners including Spiral Genetics, we expect researchers and clinicians to regularly select the Microsoft Azure cloud for its flexibility, convenience, and easy access to shared datasets.

"Several features of the Spiral Genetics BioGraph Suite fit well with our Azure platform. Once genomes are in the BioGraph Format, they have a very small online storage footprint. On Azure, this allows collaborators and authorized users to very rapidly and securely explore the same dataset according to their own needs without having to move very large data files physically around the world. Genetic data is increasingly a cornerstone of healthcare, medical science, and biology, and Microsoft looks forward to expanding our work in this field of study."

To learn more about the collaboration between Spiral Genetics and Microsoft, read the press release

Tag:

Follow the discussion

  • Oops, something didn't work.

    Getting subscription
    Subscribe to this conversation
    Unsubscribing
    Subscribing

Comments closed

Comments have been closed since this content was published more than 30 days ago, but if you'd like to continue the conversation, please create a new thread in our Forums, or Contact Us and let us know.